

## **Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18**

DENVER, CO, January 9, 2012 – **Omni Bio Pharmaceutical, Inc.** (“Omni Bio”) (**OMBPOB**), a clinical-stage biopharmaceutical company, today announced that it will present at Noble Financial Capital Markets' Eighth Annual Equity Conference being held January 17 & 18 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Dr. James Crapo, Omni Bio's chief executive officer, is scheduled to speak on Wednesday, January 18 at 1:30 p.m. Eastern time (11:30 a.m. Mountain time).

Conference and presentation details will be made available at the Omni Bio website at [www.omnibiopharma.com](http://www.omnibiopharma.com). An archived presentation will be available on the website for 30 days.

### ***About Omni Bio Pharmaceutical, Inc.***

Omni Bio Pharmaceutical, Inc. ([www.omnibiopharma.com](http://www.omnibiopharma.com)) is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug – Alpha-1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company, Bio Holding, Inc. Omni Bio's lead development program has been funding research and a human clinical trial to evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders. Omni Bio is also a significant investor in BioMimetix Pharmaceutical, Inc. (BioMimetix), a recently formed biopharmaceutical corporation. BioMimetix is the exclusive licensee of an issued patent held by Duke University, and intends to develop a new class of patented compounds for the treatment of various diseases including radiation toxicity during the treatment of cancer using radiation therapy.

Omni Bio Pharmaceutical, Inc.  
Bob Ogden  
Chief Financial Officer – Investor Relations  
(720) 488-4708  
Email – [investor\\_relations@omnibiopharma.com](mailto:investor_relations@omnibiopharma.com)

WestMountain Asset Management  
Steve Anderson – Public Relations  
(970) 212-4770  
Email – [ir@westmountainam.com](mailto:ir@westmountainam.com)